• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IPA Announces Resignation of Chief Financial Officer

    12/31/24 7:56:00 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPA alert in real time by email

    ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time.

    "Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors."

    IPA has initiated a CFO succession process and will provide updates as appropriate.

    About ImmunoPrecise Antibodies Ltd.

    ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family").

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as "expects", "estimates", "intends", "anticipates", or "believes", or variations of such words and phrases, or state that certain actions, events, or results "may", "would", "might", or "will" be taken, occur, or be achieved. Forward-looking statements include, but are not limited to, the expected results of our search for a successor to the Chief Financial Officer, the results from our financial strategy and growth objectives. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the United States, Canada or internationally. You should also consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties.

    Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to several factors and risks, as discussed in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (which may be viewed on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this release. The forward-looking statements contained in this release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241231517081/en/

    Get the next $IPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IPA

    DatePrice TargetRatingAnalyst
    12/2/2022$9.00Buy
    H.C. Wainwright
    10/25/2021$12.00Buy
    Benchmark
    10/25/2021$12.00Buy
    The Benchmark Company
    More analyst ratings

    $IPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

      ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. "This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility," said Dr. Jennifer Bath, CEO of ImmunoPr

      5/21/25 8:49:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

      Tuesday, June 3rd at 11:00 a.m. EDT ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Group's virtual conference: 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow   Hosted by: Maxim Group LLC Date: June 3rd – 5th Presentation Time: Tuesday, June 3rd at 11:00AM EDT Location: Virtual (M-Vest Platform) Registration: Click here to register The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT,

      5/20/25 8:28:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

      ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai™ platform, with a direct comparison to gold-standard wet-lab methods. The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENSai's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequ

      5/12/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      2/27/24 10:33:04 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoPrecise Antibodies Ltd. (Amendment)

      SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:53:08 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:33:21 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Leadership Updates

    Live Leadership Updates

    See more
    • ImmunoPrecise Antibodies Announces Key Leadership Changes

      ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224016053/en/Kamil Isaev (Photo: Business Wire) Kamil Isaev Joins IPA's Board of Directors IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its

      2/24/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA Announces Resignation of Chief Financial Officer

      ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. "Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors." IPA has initiated a CFO succession process and will p

      12/31/24 7:56:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

      University of Washington's Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of computational tools and AI in advancing our understanding of protein structures—principles that are central to IPA's

      10/10/24 8:10:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Financials

    Live finance-specific insights

    See more

    $IPA
    SEC Filings

    See more
    • ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

      Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug disc

      3/28/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data

      3/11/25 10:17:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and

      3/5/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      5/21/25 8:00:04 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      5/12/25 9:55:49 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      4/11/25 1:43:30 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

      H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

      12/2/22 8:15:24 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

      Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:31:59 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

      The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:28:32 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care